Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
2.
Am J Hematol ; 98(6): 922-931, 2023 06.
Article in English | MEDLINE | ID: mdl-36964937

ABSTRACT

The aim of this study was to evaluate how comorbidities and molecular landscape relate to outcome in patients with acute myeloid leukemia (AML) aged 60 years or older who received intensive induction therapy. In 91 patients, 323 mutations were identified in 77 genes by next-generation sequencing, with a median of four mutations per patient, with NPM1, FLT3, TET2, and DNMT3A being the most frequently mutated genes. A multistate model identified FLT3, IDH2, RUNX1, and TET2 mutations as associated with a higher likelihood of achieving complete remission while STAG2 mutations were associated with primary refractory disease, and DNMT3A, FLT3, IDH2, and TP53 mutations with mortality after relapse. Ferrara unfitness criteria and performance status were the best predictors of short-term outcome (area under the curve = 82 for 2-month survival for both parameters), whereas genomic classifications better predicted long-term outcome, with the Patel risk stratification performing the best over the 5-year follow-up period (C-index = 0.63 for event-free and overall survival). We show that most genomic prognostic classifications, mainly used in younger patients, are useful for classifying older patients, but to a lesser extent, because of different mutational profiles. Specific prognostic classifications, incorporating performance status, comorbidities, and cytogenetic/molecular data, should be specifically designed for patients over 60 years.


Subject(s)
Leukemia, Myeloid, Acute , Nucleophosmin , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/genetics , Risk Factors , Mutation , Prognosis
3.
Genes Chromosomes Cancer ; 62(3): 139-151, 2023 03.
Article in English | MEDLINE | ID: mdl-36412977

ABSTRACT

Myelodysplastic syndromes (MDS) are hematological malignancies classically defined by the presence of cytopenia(s) and dysmorphic myeloid cells. It is now known that MDS can be preceded by a pre-malignant condition called clonal cytopenia of unknown significance (CCUS), which associates a clonality marker with cytopenia in the absence of criteria of dysplasia. However, to date, it is not clear whether chromosomal abnormalities should be considered in the definition of CCUS or if they carry a prognostic impact in CCUS patients. In this study, we analyzed the clinico-biological features and outcomes of 34 patients who presented with one or more cytopenias, an absence of significant dysplasia, and a presence of a chromosomal abnormality (CA). We named this entity chromosomal abnormality with cytopenia of undetermined significance (CACtUS). We show that these patients are slightly older than MDS patients and that they more frequently presented with normocytic anemia. Most CACtUS patients exhibited only one unbalanced CA. The number and type of mutations were comparable between CACtUS patients and MDS patients. Regardless of the cytogenetic abnormality, the clinicobiological characteristics, overall survival, and risk of progression to high-risk (HR) MDS were similar between CACtUS patients and low-risk MDS patients. Thus, we suggest that CACtUS patients can be considered as HR-CCUS and should receive the follow-up regimen recommended for MDS patients.


Subject(s)
Anemia , Chromosome Disorders , Hematologic Neoplasms , Myelodysplastic Syndromes , Humans , Chromosome Aberrations , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology , Mutation
4.
Blood Adv ; 6(2): 386-398, 2022 01 25.
Article in English | MEDLINE | ID: mdl-34638130

ABSTRACT

Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral cytopenias and in a substantial proportion of cases to acute myeloid leukemia. The deletion of the long arm of chromosome 11, del(11q), is a rare but recurrent clonal event in MDS. Here, we detail the largest series of 113 cases of MDS and myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) harboring a del(11q) analyzed at clinical, cytological, cytogenetic, and molecular levels. Female predominance, a survival prognosis similar to other MDS, a low monocyte count, and dysmegakaryopoiesis were the specific clinical and cytological features of del(11q) MDS. In most cases, del(11q) was isolated, primary and interstitial encompassing the 11q22-23 region containing ATM, KMT2A, and CBL genes. The common deleted region at 11q23.2 is centered on an intergenic region between CADM1 (also known as Tumor Suppressor in Lung Cancer 1) and NXPE2. CADM1 was expressed in all myeloid cells analyzed in contrast to NXPE2. At the functional level, the deletion of Cadm1 in murine Lineage-Sca1+Kit+ cells modifies the lymphoid-to-myeloid ratio in bone marrow, although not altering their multilineage hematopoietic reconstitution potential after syngenic transplantation. Together with the frequent simultaneous deletions of KMT2A, ATM, and CBL and mutations of ASXL1, SF3B1, and CBL, we show that CADM1 may be important in the physiopathology of the del(11q) MDS, extending its role as tumor-suppressor gene from solid tumors to hematopoietic malignancies.


Subject(s)
Cell Adhesion Molecule-1/metabolism , Leukemia, Myeloid, Acute , Myelodysplastic Syndromes , Animals , Cell Adhesion Molecule-1/genetics , Chromosome Deletion , Chromosomes, Human, Pair 11 , Female , Genes, Tumor Suppressor , Humans , Leukemia, Myeloid, Acute/genetics , Mice , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology
5.
Leukemia ; 34(5): 1342-1353, 2020 05.
Article in English | MEDLINE | ID: mdl-31768015

ABSTRACT

Relapse is a major complication of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate chimerism monitoring on the CD3-negative mononuclear cells by RQ-PCR to predict relapse of patients allografted for AML and to compare its performance with WT1 quantification. A cohort of 100 patients undergoing allogenic SCT for AML was retrospectively analyzed in a single institution. Patients without complete chimerism, defined as less than 0.01% of recipient's DNA in CD3-negative cells, had a significantly higher risk of relapse and a lower overall survival (p < 0.001). An increase in the percentage of recipient DNA in CD3-negative cells was associated with an increased risk of relapse (p < 0.001) but not with overall survival. Comparable performances between monitoring of CD3-negative cell chimerism and WT1 expression to predict relapse was observed up to more than 90 days before hematological relapse, with sensitivity of 82% and 78%, respectively, and specificity of 100% for both approaches. Quantitative specific chimerism of the CD3-negative mononuclear fraction, enriched in blastic cells, is a new and powerful tool for monitoring measurable residual disease and could be used for AML patients without available molecular markers.


Subject(s)
Biomarkers, Tumor/metabolism , CD3 Complex/metabolism , Chimerism , Hematopoietic Stem Cell Transplantation/mortality , Leukemia, Myeloid, Acute/pathology , Neoplasm Recurrence, Local/pathology , Neoplasm, Residual/pathology , Adolescent , Adult , Aged , Female , Follow-Up Studies , Humans , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/therapy , Male , Middle Aged , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/therapy , Neoplasm, Residual/metabolism , Neoplasm, Residual/therapy , Prognosis , Retrospective Studies , Survival Rate , Transplantation, Homologous , WT1 Proteins/metabolism , Young Adult
6.
Blood Cells Mol Dis ; 75: 35-40, 2019 03.
Article in English | MEDLINE | ID: mdl-30612065

ABSTRACT

Classical Philadelphia-negative myeloproliferative neoplasms include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). They are characterized by the presence of driver mutations of JAK2, CALR or MPL genes. Overexpression of WT1 is used as a marker of minimal residual disease in acute myeloid leukemia, especially after allogeneic stem cell transplantation (SCT). We investigated WT1 expression at diagnosis in 152 MPN patients and showed that the WT1 transcript was overexpressed in PMFs and PVs compared to controls. In particular, WT1 transcript levels were higher in PMF than in ET and PV. WT1 transcript levels were significantly increased during myelofibrotic transformation of ET or PV. Using multivariate linear regression, high WT1 transcript levels in PMF were associated with age over 65, splenomegaly and thrombocytopenia. The ROC curve analysis showed that a level of WT1 transcript >10 WT1 copies/104ABL1 enabled the diagnosis of PMF with a specificity of 95.8% (PMF vs ET; ROC AUC = 0.91). In myelofibrosis, studying follow-ups of WT1 transcript showed that this marker is of interest after allogeneic SCT. These results demonstrate that WT1 overexpression is a simple marker of myelofibrosis in MPN and could be used during patient follow-up.


Subject(s)
Myeloproliferative Disorders/diagnosis , Primary Myelofibrosis/diagnosis , WT1 Proteins/genetics , Adult , Aged , Aged, 80 and over , Allografts , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia, Myeloid, Acute , Middle Aged , Neoplasms/diagnosis , Polycythemia Vera , RNA, Messenger/blood , ROC Curve , Thrombocythemia, Essential
7.
Eur J Haematol ; 101(4): 570-574, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30007088

ABSTRACT

Donor cell leukemia (DCL) is an infrequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Its true incidence is difficult to assess, although improvements in chimerism studies contributed to a better diagnosis of DCL. We report two rare cases of donor cell-derived acute promyelocytic leukemia (APL). To our knowledge, only two cases have been described in the literature. Here, we report one male and one female patients with acute myeloid leukemia (AML), who developed an APL in donor cells after HSCT. The latency between HSCT and DCL was 279 and 43 months, respectively. Fluorescent in situ hybridation and chimerism monitoring analysis proved the donor origin of APL. Surprisingly, donor lymphocyte infusion provided a hematological response during 19 months in the female patient. The mechanisms associated with pathogenesis of DCL are unclear and seem to be multifactorial. Increasing worldwide allogeneic hematopoietic stem cell transplantation activity and potentially the age of donor could explain the increasing incidence of DCL in the future. It is highlighted that long-term follow up of recipients will allow to report all cases of DCL, to clarify the genetic landscape and factors which contribute to DCL, to understand the response to DLI.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/etiology , Tissue Donors , Adult , Biomarkers , Biopsy , Bone Marrow/pathology , Female , Graft vs Host Disease/diagnosis , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/methods , Humans , Male , Middle Aged , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Transplantation, Homologous
9.
Ann Biol Clin (Paris) ; 74(1): 110-6, 2016.
Article in French | MEDLINE | ID: mdl-26878615

ABSTRACT

An acute myeloid leukemia was diagnosed in a 53-year-old female patient. She received an allogeneic stem cell transplant. After this transplant, some neutrophils with hyposegmented nucleus and abnormal chromatin clumping appeared in the peripheral blood, and their number gradually increased. The hypothesis of early relapse after transplant was ruled out and drug-related anomaly was suspected. The authors discuss about morphological features of constitutional and acquired Pelger-Huët anomaly. In the patient reported here, ciclosporine seemed to be involved in the phenomenon, as the morphological anomaly of the neutrophils gradually decreased after the drug was discontinued.


Subject(s)
Chromatin/pathology , Cyclosporine/adverse effects , Drug-Related Side Effects and Adverse Reactions/diagnosis , Granulocytes/pathology , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/therapy , Pelger-Huet Anomaly/etiology , Chromatin/drug effects , Chromatin/metabolism , Diagnosis, Differential , Female , Granulocytes/drug effects , Granulocytes/metabolism , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia, Myeloid, Acute/blood , Middle Aged , Pelger-Huet Anomaly/chemically induced , Pelger-Huet Anomaly/diagnosis , Recurrence , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Transplantation, Homologous/adverse effects
10.
J Clin Lab Anal ; 26(5): 376-83, 2012 Sep.
Article in English | MEDLINE | ID: mdl-23001984

ABSTRACT

Estimated glomerular filtration rate (eGFR) methods are not sufficiently reliable in renal transplant recipients (RTR) and should be replaced by iohexol plasma clearance measurement. However, this method has poor availability in health centers. The aim of our study was to develop a high-performance liquid chromatography (HPLC) method for plasma iohexol measurement in routine practice and to evaluate its plasma clearance as a reference of GFR. We developed an HPLC method using UV detection. We evaluated sample storage conditions to provide recommendations for routine practice. Then, we compared GFRbased on plasma iohexol clearance (GFR-iohexol) to eGFR using modification of diet in renal disease, Cockcroft and Gault, and CDK-EPIequations in 40 RTR. The method was validated over a concentration range of 15-300 µg/l. Excellent linearity (r > 0.998), inter- and intraday precision (CV < 3.3%), and accuracy (>96.8%) were complied with ICH guidelines. We also demonstrated excellent samples stability (9 days). Although eGFR methods are not references in RTR, we found a correct concordance between eGFR and GFR-iohexol in our population. To conclude, our method is simple, rapid, accurate, and reliable for routine clinical and research use especially in RTR.


Subject(s)
Blood Chemical Analysis/methods , Chromatography, High Pressure Liquid/methods , Glomerular Filtration Rate/physiology , Iohexol/analysis , Kidney Transplantation , Adult , Aged , Drug Stability , Female , Humans , Iohexol/chemistry , Iohexol/metabolism , Linear Models , Male , Metabolic Clearance Rate/physiology , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
11.
J Neurol Sci ; 303(1-2): 124-7, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21276595

ABSTRACT

BACKGROUND: Dysregulation of iron homeostasis is one possible pathophysiological mechanism involved in motor neuron degeneration in amyotrophic lateral sclerosis (ALS). SLC11A2 gene encodes the divalent metal transport 1 (DMT1) mediating iron transport in cerebral endosomal compartments. The objective of the study was to analyze DMT1 as a possible risk or modulating factor in sporadic ALS (SALS). METHODS: We performed a case-control association study on an intronic polymorphism (rs407135) previously analyzed in another neurodegenerative disease, Alzheimer's disease. This polymorphism was studied by DNA sequencing in 579 French patients with SALS and 517 healthy matched individuals. The clinical characteristics of patients were analyzed in relation to their genotypes. RESULTS: We observed that the C allele of rs407135 in SLC11A2 was associated with a shorter disease duration in SALS patients with onset in the legs [Hazard ratio: 1.5 [1.1-2.1] (p=0.02)]. These results are in line with previous observations suggesting that bulbar and spinal motor neurons have different metabolic regulation and gene expression profiles. CONCLUSIONS: Our findings support an implication for iron metabolism in ALS and suggest that the genotype of the SLC11A2 gene could modulate the duration of the disease in French SALS patients.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Cation Transport Proteins/genetics , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Alleles , Case-Control Studies , Cohort Studies , DNA/genetics , Female , Gene Frequency , Genotype , Humans , Iron/metabolism , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Mutation/physiology , Reverse Transcriptase Polymerase Chain Reaction , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL